$7.61
0.66%
Nasdaq, Apr 21, 07:49 pm CET
ISIN
US92556V1061
Symbol
VTRS

Viatris Stock price

$7.56
-1.69 18.27% 1M
-4.15 35.44% 6M
-4.89 39.28% YTD
-3.54 31.89% 1Y
-3.15 29.41% 3Y
-8.55 53.07% 5Y
-62.26 89.17% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.17 2.30%
ISIN
US92556V1061
Symbol
VTRS
Sector
Industry

Key metrics

Market capitalization $9.02b
Enterprise Value $22.51b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 11.39
EV/Sales (TTM) EV/Sales 1.53
P/S ratio (TTM) P/S ratio 0.61
P/B ratio (TTM) P/B ratio 0.48
Dividend yield 6.35%
Last dividend (FY24) $0.48
Revenue growth (TTM) Revenue growth -4.58%
Revenue (TTM) Revenue $14.68b
EBIT (operating result TTM) EBIT $1.05b
Free Cash Flow (TTM) Free Cash Flow $1.98b
Cash position $829.60m
EPS (TTM) EPS $-0.53
P/E forward 53.26
P/S forward 0.65
EV/Sales forward 1.63
Short interest 4.27%
Show more

Is Viatris a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Viatris Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Viatris forecast:

4x Buy
36%
6x Hold
55%
1x Sell
9%

Analyst Opinions

11 Analysts have issued a Viatris forecast:

Buy
36%
Hold
55%
Sell
9%

Financial data from Viatris

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
14,677 14,677
5% 5%
100%
- Direct Costs 8,825 8,825
0% 0%
60%
5,852 5,852
11% 11%
40%
- Selling and Administrative Expenses 1,101 1,101
16% 16%
8%
- Research and Development Expense 807 807
1% 1%
5%
3,944 3,944
18% 18%
27%
- Depreciation and Amortization 2,893 2,893
6% 6%
20%
EBIT (Operating Income) EBIT 1,051 1,051
49% 49%
7%
Net Profit -634 -634
1,259% 1,259%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Viatris directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viatris Stock News

Neutral
PRNewsWire
about 2 hours ago
LOS ANGELES , April 21, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS). IF YOU SUFFERED A LOSS ON YOUR VIATRIS INVESTMENTS, CLICK HERE BEFORE JUNE 3, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUI...
Neutral
PRNewsWire
about 6 hours ago
PHILADELPHIA , April 21, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the "Class Period"). Investor Deadline: Investors who purchased or acquired Viatris  sec...
Neutral
PRNewsWire
about 8 hours ago
Aiming to address a significant unmet need for which no other approved treatment option is available for generalized anxiety disorder patients in Japan PITTSBURGH , April 21, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has filed applications to the Ministry of Health, Labor and Welfare (MHLW) for approval of Effexor SR Capsules (venlafaxine ...
More Viatris News

Company Profile

Viatris, Inc. engages in the commercialization and manufacturing of pharmaceutical products. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Head office United States
CEO Scott Smith
Employees 32,000
Founded 2019
Website www.viatris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today